Opinion

Video

Safety Outcomes with Leuprolide

Author(s):

Paul Sieber, MD

In the second interview of the series, Paul Sieber, MD, provides expert insights on the management of adverse effects seen in patients receiving leuprolide for the treatment of advanced/metastatic prostate cancer.

Related Videos
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
1 expert in this video
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
An Overview of the ARANOTE Trial
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Nitin Yerram, MD, on a liquid biopsy urine test for prostate cancer
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Stephen J. Freedland, MD, on the benefits of mCRPC treatments translating to the real world
Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Study data point to gender disparities in oncology research citations
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Related Content
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr_Microbe - stock.adobe.come
May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke
Use of focal therapy was shown to prolong the duration of active surveillance.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: @ Dr_Microbe - stock.adobe.com
May 2nd 2025

Phase 3 trial of capivasertib in mCRPC discontinued following IDMC recommendation

Hannah Clarke
The committee determined that the study was unlikely to meet its dual primary end points of radiographic progression-free survival and overall survival.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
ARANOTE substudy highlights benefits of darolutamide in Black men
April 28th 2025

ARANOTE substudy highlights benefits of darolutamide in Black men

Benjamin P. Saylor
The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in Black men.
Stephen J. Freedland, MD
April 28th 2025

Most men in EMBARK trial recover T levels following treatment suspension

Benjamin P. Saylor
More than 80% of patients in both groups had a full recovery of testosterone.
© 2025 MJH Life Sciences

All rights reserved.